What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial
- 27 September 2014
- journal article
- research article
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 265 (2) , 107-116
Abstract
The aim of this study was to evaluate residual symptoms in patients achieving remission according to the consensus criteria and to analyze their potential influence on the patient’s outcome one year after discharge. In total, 399 patients suffering from a schizophrenia spectrum disorder were evaluated within a naturalistic study. Remission status was examined using the consensus criteria. Residual symptoms were defined as any symptom present at the time-point of remission following analogous analyses performed in depressed patients. Therefore, a PANSS item with a symptom severity of >1 (= at least borderline mentally ill) was defined to be a residual symptom. Remitters with and without residual symptoms were compared regarding psychopathology, functioning and side effects. In total, 236 patients (59 %) were remitters at discharge with 94 % of them suffering from at least one residual symptom. The most common residual symptoms were blunted affect (49 %), conceptual disorganization (42 %) and social withdrawal (40 %). A significant association was found between the presence of residual symptoms and the severity of side effects (p < 0.0001) and functioning (p = 0.0003) at discharge as well as between residual symptoms and the risk of relapse and chance of remission one year after discharge. Residual symptoms were highly prevalent in remitted schizophrenia inpatients following the suggested definition. Most residual symptoms were persistent baseline symptoms suggesting an ongoing illness severity. Also, the necessity to re-evaluate the consensus criteria questioning the status of remission in these patients is also pointed out.Keywords
This publication has 37 references indexed in Scilit:
- Identifying persistent negative symptoms in first episode psychosisBMC Psychiatry, 2012
- A Critical Analysis and Discussion of the Appropriateness of the Schizophrenia Consensus Remission Criteria in Clinical Pharmaceutical TrialsPharmacopsychiatry, 2010
- Outcome of first-episode schizophrenia in India: longitudinal study of effect of insight and psychopathologyThe British Journal of Psychiatry, 2010
- Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic SchizophreniaSchizophrenia Bulletin, 2008
- Sociodemographic and clinical factors associated with relapse in schizophreniaPsychiatry and Clinical Neurosciences, 2007
- Improving patient outcomes in schizophrenia: achieving remissionJournal of Psychopharmacology, 2006
- Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disordersEuropean Archives of Psychiatry and Clinical Neuroscience, 2006
- Pharmacological approaches to the treatment of residual symptomsJournal of Psychopharmacology, 2006
- Prodromal Symptoms of Relapse in Schizophrenic Outpatients: Retrospective and Prospective StudyPsychiatry and Clinical Neurosciences, 1993
- The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patientsActa Psychiatrica Scandinavica, 1987